Physician profile
Vimal C Sharma
NPI 1952468795
$9,906.72
in general payments reported to CMS, 2019-2025
37 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $1,318 · 2021: $1,633 · 2022: $1,760 · 2023: $1,292 · 2024: $1,152 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.50 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,119.68 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $1,060.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $945.06 | 2019-2025 | Nucala, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $925.52 | 2021-2025 | |
| Novo Nordisk INC | $882.15 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $669.79 | 2021-2025 | Qulipta, Ubrelvy, Rinvoq |
| Pfizer INC. | $440.98 | 2019-2025 | |
| Mylan Specialty L.P. | $435.41 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $292.02 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $291.57 | 2019-2025 | |
| Amgen INC. | $268.48 | 2019-2024 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $241.21 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.49 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $165.47 | 2019-2024 | Eliquis |
| Esperion Therapeutics, INC. | $127.37 | 2020-2025 | Nexletol |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $108.42 | 2019-2021 | |
| Abbott Laboratories | $104.49 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $57.48 | 2021 | |
| Viatris Specialty LLC | $56.80 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $53.53 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $51.12 | 2021 | |
| Exact Sciences Corporation | $48.49 | 2025 | The Cologuard Plus Collection Kit |
| Eisai INC. | $32.96 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $32.79 | 2022 | |
| Radius Health, INC. | $32.55 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $24.42 | 2021 | |
| Grifols USA, LLC | $23.88 | 2020 | |
| Inspire Medical Systems, INC. | $23.67 | 2025 | Inspire |
| Electromed, INC. | $22.99 | 2021 | |
| Astellas Pharma US INC | $21.69 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $19.33 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $18.52 | 2019 | |
| Allergan, INC. | $18.48 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.00 | 2025 | Keveyis |
| Alfasigma USA, INC. | $15.39 | 2020 | |
| Therapeuticsmd, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimal Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.